pf-03715455
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01186757)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1- Mol. weight
- 700.29 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1938400 ↗
Also known as
- pf03715455
- pf 03715455
- pf-03715455
- pf-03715455
- pf-03715455
- pf-03715455
- pf-03715455
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02366637 | Phase 2 | Jan 1, 2015 | Pfizer |
| NCT02219048 | Phase 2 | Nov 1, 2014 | Pfizer |
| NCT01314885 | Phase 1 | Jan 1, 2011 | Pfizer |
| NCT01186757 | Phase 1 | Aug 1, 2010 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 2 | 2010 |
1 organizations
Page 1 / 1